Adults with partial-onset seizures: XCopri approved by FDA

The FDA ( U.S. Food and Drug Administration ) has approved XCopri ( Cenobamate tablets ) to treat partial-onset seizures in adults.

A seizure is a usually short episode of abnormal electrical activity in the brain. Seizures can cause uncontrolled movements, abnormal thinking or behavior, and abnormal sensations. Movements can be violent, and changes in consciousness can occur.
Seizures occur when clusters of neurons in the brain undergo uncontrolled activation. A partial-onset seizure begins in a limited area of the brain.

The safety and efficacy of XCopri to treat partial-onset seizures was established in two randomized, double-blind, placebo-controlled studies that enrolled 655 adults.
In these studies, patients had partial-onset seizures with or without secondary generalization for an average of approximately 24 years and median seizure frequency of 8.5 seizures per 28 days during an 8-week baseline period.
During the trials, doses of 100, 200, and 400 mg daily of XCopri have reduced the percent of seizures per 28 days compared with the placebo group.
The recommended maintenance dose of XCopri, following a titration ( medication adjustment ) period, is 200 mg daily; however, some patients may need an additional titration to 400 mg daily, the maximum recommended dose, based on their clinical response and tolerability.

DRESS ( Drug Reaction with Eosinophilia and Systemic Symptoms ), also known as multiorgan hypersensitivity, has been reported among patients taking XCopri.
In the clinical trials, some patients experienced DRESS, and one patient died, when XCopri was titrated rapidly ( weekly or faster titration ).
No cases of DRESS were reported in an open-label safety study of 1,339 epilepsy patients when XCopri was started at 12.5 mg per day and adjusted every two weeks; however, this finding does not show that the risk of DRESS is prevented by a slower titration.

A higher percentage of patients who took XCopri also had a shortening of the QT interval ( an assessment of certain electrical properties of the heart ) of greater than twenty milliseconds compared to placebo.

XCopri should not be used in patients with hypersensitivity to Cenobamate or any of the inactive ingredients in XCopri or Familial Short QT syndrome.
QT shortening can be associated with ventricular fibrillation, a serious heart rhythm problem.

Antiepileptic drugs, including XCopri, increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication.
Patients taking an Antiepileptic drug for any indication should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior.

XCopri may cause neurological adverse reactions, including somnolence and fatigue, dizziness, trouble with walking and coordination, trouble with thinking, and visual changes.
Patients should also be advised not to drive or operate machinery until the effect of XCopri is known.

The most common side effects that patients in the clinical trials reported were somnolence, dizziness, fatigue, diplopia ( double vision ), and headaches. ( Xagena )

Source: FDA, 2019



Altri articoli

The FDA ( U.S. Food and Drug Administration ) has approved Xcopri ( Cenobamate tablets ) to treat partial-onset seizures...

The positive results of the first pivotal phase 3 study of the investigational medicine Epidiolex ( Cannabidiol or CBD )...

The aim of a study was to evaluate the efficacy and safety of the new antiepileptic drug Brivaracetam ( Briviact...

Brivaracetam ( UCB 34714; Briviact ) is an add-on treatment for adult patients with partial seizures. Similar to Levetiracetam (...

In February 2014, the American Heart Association [ AHA ] /American Stroke Association [ ASA ] released their first guideline...

Preliminary efficacy and safety data on 27 children and young adults with treatment-resistant epilepsy who have been treated with an...

A phase III clinical trial ( Study 332 ) of AMPA receptor antagonist Perampanel ( Fycompa ) has met its...

A study ( Study 307 ) has evaluated safety, tolerability, seizure frequency, and regional variations in treatment responses with the...

Sudden unexpected death in epilepsy ( SUDEP ) is the leading cause of death in people with chronic refractory epilepsy....